1	INDICATIONS AND USAGE
GEODON is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. GEODON intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other an tipsychotic drugs [ )]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [ ]
see
Warnings and Precautions (5.2
see
Warnings and Precautions (5.2)
GEODON is an atypical antipsychotic. In choosing among treatments, prescribers should be aware of the capacity of GEODON to prolong the QT interval and may consider the use of other drugs first ( )
5.2
GEODON is indicated as an oral formulation for the:
Treatment of schizophrenia. ( )
1.1
Adults:
Efficacy was established in four 46 week trials and one maintenance trial
in adult patients with schizophrenia ( )
14.1
Acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder ( )
1.2
Adults:
Efficacy was established in two 3-week trials in adult patients with manic or mixed episodes. ( )
14.2
Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate. ( )
1.2
Adults:
Efficacy was established in one maintenance trial in adult patients. ( )
14.2
GEODON as an intramuscular injection is indicated for the:
Acute treatment of agitation in schizophrenic patients. ( )
1.3
Adults:
Efficacy was established in two short-term trials in agitated patients with schizophrenia. ( )
1.3
1.1 Schizophrenia
Geodon is indicated for the treatment of schizophrenia. The efficacy of oral ziprasidone was established in four short-term (4- and 6-week) controlled trials of adult schizophrenic inpatients and in one maintenance trial of stable adult schizophrenic inpatients [ ].
see
Clinical Studies (14.1)
1.2 Bipolar I Disorder (Acute Mixed or Manic Episodes and Maintenance Treatment as an Adjunct to Lithium or Valproate)
Geodon is indicated as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder. Efficacy was established in two 3-week monotherapy studies in adult patients [ ]
see
Clinical Studies (14.2)
.
Geodon is indicated as an adjunct to lithium or valproate for the maintenance treatment of bipolar I disorder. Efficacy was established in a maintenance trial in adult patients. The efficacy of Geodon as monotherapy for the maintenance treatment of bipolar I disorder has not been systematically evaluated in controlled clinical trials [ ].
see
Clinical Studies (14.2)
1.3 Acute Treatment of Agitation in Schizophrenia
GEODON intramuscular is indicated for the treatment of acute agitation in schizophrenic patients for whom treatment with ziprasidone is appropriate and who need intramuscular antipsychotic medication for rapid control of agitation. The efficacy of intramuscular ziprasidone for acute agitation in schizophrenia was established in single day controlled trials of agitated schizophrenic inpatients [ ]
see
Clinical Trials (14.1)
"Psychomotor agitation" is defined in DSM-IV as "excessive motor activity associated with a feeling of inner tension". Schizophrenic patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation.
Since there is no experience regarding the safety of administering ziprasidone intramuscular to schizophrenic patients already taking oral ziprasidone, the practice of co-administration is not recommended.
Ziprasidone intramuscular is intended for intramuscular use only and should not be administered intravenously.